DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
TEL AVIV, Israel and AHMEDABAD, India, July 05, 2017 -- (NASDAQ:PAHC)
Phibro Animal Health Corporation and Zydus Cadila today announced their intention to enter into a long-term arrangement to license Phibro’s innovative poultry vaccine technologies and know-how to a new vaccine manufacturing facility to be built by Zydus Cadila to serve the fast growing poultry market in India.
Jack Bendheim, Chairman, President and Chief Executive Officer of Phibro, remarked, “We are proud of the more than 20-year partnership with Zydus Cadila serving the Indian animal health market and we view this as an exciting next step in our relationship.”
Speaking on the development Mr. Pankaj R. Patel, Chairman and Managing Director, Zydus group said, “Our endeavor has always been to enable access to innovative therapies across geographies and this agreement with Phibro will help bring innovations to the poultry market in India. The availability of new advanced poultry vaccines, which were until now being imported into India, adds a new dimension to the Make-in-India movement in the animal health segment.”
About Zydus Animal Health
With a strong presence in the livestock and poultry segments, Zydus Animal Health is India’s leading animal healthcare player and a market leader in various therapeutic segments which include antibacterials, NSAIDs, antimastitis, tonics and poultry vaccines amongst others in India. Zydus Animal Health has introduced the highest number of ‘First in India’ products, in keeping with its mission to provide innovative solutions that improve animal health and farm productivity.
About Zydus Cadila
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 20000 people worldwide and is dedicated to creating healthier communities globally. The group aspires to be a research-based pharmaceutical company by 2020.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for use in the production of poultry, swine, dairy, beef cattle and aquaculture. For further information, please visit www.pahc.com.
Contact: Phibro Animal Health Corporation Richard Johnson Chief Financial Officer +1-201-329-7300 or [email protected] Sujatha Rajesh Vice President – Corporate Communications Zydus Cadila +91-997-405-1180 [email protected]
